Business

From a manufacturer’s line to the pharmacy shelf

Four capabilities decide whether a medicine reaches its market on time: registration, distribution, promotion and the projects beyond them. The group runs all four with its own people in every country it operates.

The four pillars

What the group runs in every market

None of this is subcontracted. Each pillar is staffed inside the local entity, which is why an on-time launch is something the group can commit to rather than hope for.

01
Sales & marketing
A specialised sales force in each country, with a dedicated marketing support team behind it.
- Therapy-aligned field teams calling on hospitals, clinics and pharmacies
- Marketing support that builds each brand locally rather than importing campaigns
- Coverage across public tenders and private trade alike
02
Distribution
Sound infrastructure with reach into every part of each country, held to pharmaceutical storage standards.
- Multiple stock points per market, so supply survives a single depot’s problems
- Cold-chain handling where the portfolio demands it
- Delivery into provinces, not just capitals
03
Product registration
A dedicated regulatory team in each country of operation, for on-time product launch.
- Dossiers prepared to each authority’s current expectations, not last year’s
- Fast-tracked registrations that make first-generic launches possible
- More than six hundred registrations filed or in progress across the group
04
Exclusive projects
A direct-to-customer application in development, delivering medicines to the patient’s home or workplace.
- Direct-to-customer delivery, built on the group’s own distribution
- A channel the group owns end to end, from order to doorstep
- Designed for chronic therapies, where continuity matters most

Differentiators

What the group does that a trading house cannot

Distribution gets a product to market. These are the things that decide which product, and how early it arrives.

Novel chemical entities: Introducing NCEs to markets that have never had them.
Bioequivalence studies: Commissioned where an authority requires proof, not paperwork.
Site transfers: Moving new products between manufacturing sites without losing the registration.
First-generic launches: Frequently first to file when a molecule opens — the vision made operational.
Novel drug delivery systems: Advanced medical devices and NDDS formats ahead of the local market.

Regulatory: A strong dedicated regulatory team in each country ensures documentation is correct and registrations are fast-tracked for an early launch.
Research: A dedicated marketing and research analysis team shortlists products with real potential, and launches first generics frequently to keep an edge over the competition.
Reliability: A correct reading of the market with precise minimum order quantities, so business sees the least variation after commercialisation.

The portfolio

What the group actually moves

Three commercial markets and a portfolio weighted toward the therapy areas where a first generic is worth launching. The molecules below are from the group’s own portfolio chart.

Vietnam
US$16.5 M
300+ Registrations
Myanmar
US$3.4 M
200+ Registrations
Philippines
US$1.5 M
100+ Registrations

Portfolio by therapy area

Anti-infectives

32.2%

Cefoperazone + Sulbactam
Cefpirom
Cephalothin
Amoxiclav 1000 / 625 / 375
Meropenem
Imipenem + Cilastatin
Piperacillin + Tazobactam

Cardiovascular

26.7%

Telmisartan + Amlodipine
Valsartan + Amlodipine
Rosuvastatin
Atorvastatin
Rivaroxaban
Apixaban

Oncology

22.8%

Palonosetron
Erlotinib
Imatinib
Melphalan
Bortezomib

Anti-diabetics and others

18.3%

Repaglinide
Metformin XR 500 / 750 / 1000
Vildagliptin + Metformin
Fluticasone + Salmeterol inhaler
Citicolin injection
Methylcobalamine softgel capsules

Registrations include products registered, submitted and in progress. Turnover figures are per commercial market.

The ranges behind the figures

Registrations become brands. These eight products are marketed under Aveda, the group’s label in Myanmar — every molecule and strength below is the one printed on the pack.